Editor's note: We're at the end of 2025... When you hear from us next in the Chaikin PowerFeed, we'll be in the new year.

Editor's note: We're at the end of 2025... When you hear from us next in the Chaikin PowerFeed, we'll be in the new year. Our offices and the markets are closed tomorrow for New Year's Day. So we won't publish the PowerFeed. You can expect to receive your next issue on Friday, January 2. But today, we're back with another essay in our special series from our founder Marc Chaikin... It was published in the July 2 edition of the Chaikin PowerFeed. And in it, Marc shares a story about how life keeps improving thanks to one exciting industry... Innovation Is Still Improving Lives By Marc Chaikin, founder, Chaikin Analytics Abby Schwartz still remembers how the doctor tried to comfort her... He had just told her that her 21-month-old daughter, Sammie, had cystic fibrosis ("CF"). It's a crippling condition caused by a rare genetic mutation. The doctor tried to soften the blow. As he said...   The good news is the life expectancy for someone with CF is almost 31 years. Schwartz and her husband sat quietly. She was 31 at the time. It's a nightmare scenario for every parent. And the heartbreak must have been excruciating. CF is an awful condition to deal with. It causes thick mucus to build up in organs – including the lungs, pancreas, and intestines. Patients typically have difficulty breathing. And they get frequent infections like pneumonia and bronchitis. Schwartz spent years teaching her daughter to follow a strict regimen of more than a dozen different drugs. For example, CF interferes with the body's ability to get nutrients from food. So Sammie had to take special capsules full of pancreatic enzymes before every meal. Twice a day, Sammie needed to use a nebulizer device to thin the mucus in her lungs. She also wore a special vibrating vest to loosen the mucus. Schwartz would help by pounding on her daughter's back while she watched her favorite TV shows. It was an exhausting routine for Schwartz... Recommended Links: Woman Who Was Wronged by Wall Street Fights Back After decades of working hard, Sandy woke up to find her 401(k) in freefall. She'd lost nearly half of her retirement savings at the hands of a careless money manager. What she and her husband did next is unusual. But today it's giving regular Americans the chance to beat Wall Street at its own game – and make extraordinary potential profits as a result. Click here for the full story. Until Midnight: Doc's Special Holiday Invitation for YOU Dr. David "Doc" Eifrig has achieved the "impossible" – racking up 78 winning trades in a row and counting – with ZERO losers. Now, he's throwing a celebration, and all the "gifts" are for you. In the spirit of the holidays, Doc is sharing his best offer EVER on his No. 1 favorite strategy of all time... and the greatest, by far, for this confusing market. Click here for the full details from Doc. Managing CF Treatments Took a Big Emotional Toll She handled daily checklists of filling prescriptions and scheduling treatments – including blood tests, chest X-rays, and "sputum cultures" to check for lung infections. Early on, she joined a network of parents who also had children with CF. It was great for learning how to manage her daughter's disease. But it also came with a downside... Someone in the group would eventually lose their child. Sometimes, they were well into adulthood. Other times, they were much younger. It's upsetting to think about. Schwartz would go to the funeral and be supportive. She wrote about how it felt sitting beside two other mothers of children with CF...   We were the lucky ones whose daughters were still alive. Silent, we stared ahead, clutching one another's hands. I envisioned the three of us on a rowboat, in the middle of a storm-tossed ocean, sharks circling – waiting to tear us apart. Meanwhile, Schwartz tried to avoid thinking about how long her daughter would survive with CF. Sammie had a close call after her junior year of high school. She developed a bad lung infection. It required a long hospital stay, antibiotics, and a special airway-clearance therapy. Schwartz noticed that her daughter's lung function never fully recovered after that infection. It's an example of why CF is a "degenerative" disease – it slowly damages the lungs and other organs. In 2018, Sammie was accepted into a clinical trial for a promising new CF drug... A Breakthrough in Treatment Early results showed that it worked for most CF patients. That made it a major improvement over earlier treatments. Sammie took the drug for a few weeks. But she didn't notice any difference. However, only half of the patients in clinical trials get the drug. The other half gets a placebo that does nothing. That's how researchers test how well a drug works. They measure the difference between the two groups. When the trials moved to the next stage, Sammie received the "real" drug. The effects were almost immediate. She started coughing up mucus – a sign her lungs were clearing. The worst symptoms improved dramatically over the next few weeks... Sammie could breathe easily. Her chronic cough – which she had since middle school – disappeared completely. And she was able to stop taking insulin. The drug is called Trikafta. For CF patients, it's a literal lifesaver. And it's also a huge deal for Schwartz. As she said in the Washington Post...   I was an emotional mess the week Trikafta was approved. It felt like I'd been holding my breath for 20 years and could finally exhale. Today, Sammie – and thousands of other CF patients – can look forward to living longer, more comfortable lives thanks to Trikafta. It's also a game changer for parents. In the Washington Post, Schwartz explained how her relationship with her daughter has changed...   She no longer needs me to be her caretaker. I can just be her mom. Trikafta is one of the biggest success stories in modern medicine. It's another example of humanity's incredible progress. And it shows the power of biotech to change lives. Folks, sometimes it seems like negative news has taken over the world. Every time we turn on the TV, we see something terrible. The reality is that humanity is still making progress. Innovation is still improving lives. And it's still creating investment opportunities. Sure, the biotech sector comes with plenty of risk. But the potential to change lives – and generate big investment gains – is massive. Good investing, Marc Chaikin   ​​​​​​Editor's note: As part of this special series here at the Chaikin PowerFeed, this edition does not include the usual data from the Power Gauge below. Power Gauge users can still log on to the Chaikin Analytics platform to access our system's most recent data. Look forward to our usual PowerFeed format returning on Monday, January 5.   You have received this e-mail as part of your subscription to PowerFeed. If you no longer want to receive e-mails from PowerFeed, click here. You're receiving this e-mail at reunisoft.cryptonews@blogger.com. For questions about your account or to speak with customer service, call +1 (877) 697-6783 (U.S.), 9 a.m. - 5 p.m. Eastern time or e-mail info@chaikinanalytics.com. Please note: The law prohibits us from giving personalized financial advice. © 2025 Chaikin Analytics, LLC. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from Chaikin Analytics, LLC. 201 King Of Prussia Rd., Suite 650, Radnor, PA 19087. www.chaikinanalytics.com. Any brokers mentioned constitute a partial list of available brokers and is for your information only. Chaikin Analytics, LLC, does not recommend or endorse any brokers, dealers, or investment advisors. Chaikin Analytics forbids its writers from having a financial interest in any security they recommend to our subscribers. All employees of Chaikin Analytics, LLC (and affiliated companies) must wait 24 hours after an investment recommendation is published online – or 72 hours after a direct mail publication is sent – before acting on that recommendation. This work is based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility.